Dostarlimab - GSK
Alternative Names: ANB 011; Dostarlimab-gxly; GSK-4057190; JEMPERLI; Jemperli; TSR 042; WBP 285Latest Information Update: 10 Jun 2024
At a glance
- Originator AnaptysBio
- Developer GSK; Italian Sarcoma Group
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Endometrial cancer; Solid tumours
- Phase III Colorectal cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Squamous cell cancer
- Phase II/III Non-small cell lung cancer
- Phase II Breast cancer; Cervical cancer; Clear cell sarcoma; Liver cancer; Malignant melanoma; Neuroendocrine tumours; Pancreatic cancer; Rectal cancer; Small cell lung cancer
Most Recent Events
- 03 Jun 2024 Efficacy data from a phase II trial in Solid tumors by GSK
- 31 May 2024 Adverse events data from the phase III trial in Endometrial cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASC0-2024)
- 31 May 2024 Updated efficacy data from a phaseII trial in Rectal cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)